Develops an antibody drug candidate for atopic dermatitis and other autoimmune and inflammatory diseases.
10-K for FY2025, filed Mar 10, 2026We are a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory…View ↗
The company earns money from licensing its intellectual property and collaborating with other companies. Agreements can provide upfront payments, research and development funding, milestone payments, and royalties on sales of approved products.
10-K for FY2025, filed Mar 10, 2026The principal activities from which the Company generates revenue include licensing agreements and collaboration agreements. License…View ↗
$800K
10-K for FY2025, filed Mar 10, 2026
$800K ↗
Other companies enter licensing and collaboration agreements for the company's intellectual property and for research, development and commercialization activities.
10-K for FY2025, filed Mar 10, 2026The principal activities from which the Company generates revenue include licensing agreements and collaboration agreements. License…View ↗
No. It lost $45.3M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$15.6MView ↗
8-K, filed Jul 23, 2026
On July 20, 2026, ImageneBio, Inc., a Delaware corporation (the “Company”), based in part on the recommendation of Kristin Yarema, Ph.D.…View ↗
Shrinking. Revenue fell 97% in 4 years, from $31M in FY2021 to $800K in FY2025, about 60% a year.
From oncology to inflammatory disease
The older report centered on targeted cancer medicines for biomarker-defined tumors, including programs across the Hippo, RAS and immune-signaling pathways. The latest report focuses on a therapeutic for autoimmune and inflammatory diseases, initially atopic dermatitis.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Mar 10, 2026We are a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs.…View ↗
We are a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory…View ↗
Competes with Sanofi/Regeneron, Leo Pharmaceuticals, Eli Lilly, Galderma Laboratories, Pfizer, AbbVie, Nektar Therapeutics, Apogee Therapeutics, Kymera Therapeutics, Aclaris Therapeutics, Corvus Pharma, UCB Pharma, Sanofi, Amgen, Kyowa Kirin, Abcellera, Astria, BioCryst, and Navigator Medicines
10-K for FY2025, filed Mar 10, 2026There are several approved products for moderate-to-severe AD, such as DUPIXENT® (dupilumab), an IL-4Ra mAb marketed by Sanofi/Regeneron…View ↗
Loading...